Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dyno-hc9
- Development stage
- Preclinical
- Lead developer
- Dyno Therapeutics
- Modality
- Recombinant Proteins and Enzymes, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intravenous
01
Overview
Dyno-hc9 (also known as Dyno bCap 1) is an AI-designed adeno-associated virus (AAV) capsid developed by Dyno Therapeutics. It is optimized for efficient gene delivery to the brain and central nervous system (CNS), offering improved transduction efficiency compared to standard AAV capsids such as AAV9. The technology enables widespread CNS delivery via intravenous injection, with significant liver detargeting and a mechanism for crossing the blood-brain barrier that is conserved between non-human primates and humans. This makes it a promising vector for next-generation gene therapies targeting neurological diseases[1].
- Brand names
- Dyno-hc9Dyno-hc-9Dyno-hc 9Dyno bCap 1
Beyond the preview
Go deeper on Dyno-hc9.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dyno-hc9.